# MOTS-c — dosage, half-life & reference guide | PepVault

Source: https://pepvault.app/peptides/mots-c

Last updated: 2026-09-26

[Library](https://pepvault.app/peptides) [Longevity](https://pepvault.app/peptides#longevity) reviewed September 2026

# MOTS-c Dosage, half-life & reference guide

Also known as Mitochondrial Open Reading Frame of the 12S rRNA-c

A peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell. In mice it activates AMPK, the pathway exercise triggers, improving insulin sensitivity and exercise capacity, which is why it's called an "exercise mimetic".

- **Studied range:** 5–10 mg
- **How often:** 2–3× weekly
- **Half-life:** Hours
- **Evidence:** Emerging
- **Routes:** SubQ, IM

Studied in research — not a recommendation.

[MOTS-c dose guide](https://pepvault.app/lab/dosage/mots-c)

## How it works.

Mitochondria-derived peptide that regulates metabolic homeostasis. In mouse and cell studies it activates the AMPK pathway, improves insulin sensitivity and exercise capacity, and slows some signs of aging.

**Commonly reported:** More energy and better workout endurance over the first weeks, sometimes after a week or two of feeling tired. No human trial has tested it yet.

## Where MOTS-c works.

- ### Appetite & metabolism

  **In animals.** In mice it activates AMPK, the pathway exercise triggers, improving insulin sensitivity and exercise capacity.
- ### Muscle

  **In animals.** Commonly reported in weeks 2 to 4: workouts feel a little easier and endurance pushes further.
- ### Energy & longevity

  **In animals.** A peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

## Week by week.

What to expect in the first 8 weeks

- **Onset:** 1–2 weeks
- **Peak effect:** 4–8 weeks
- **Duration:** 4–8 weeks

1. Day 1–14 Animal

   ### The first two weeks

   Commonly reported in the first two weeks: steadier energy for some, tiredness or feeling flat for others while the body adjusts. MOTS-c switches on AMPK, the metabolic pathway exercise uses, shown so far in mice.

   The science

   Mechanism: MOTS-c activates AMPK → GLUT4 translocation → increased glucose uptake in skeletal muscle, plus upregulated fatty acid oxidation. In a way, it's an "exercise mimetic" — your cells are getting the same metabolic signal they'd get from a workout, at the mitochondrial level.

   Sources

   - Lee et al. (2015)

   Updated Sep 2026
2. Day 14–28 Animal

   ### Workouts often feel easier

   Commonly reported in weeks 2 to 4: workouts feel a little easier and endurance pushes further. In mice, MOTS-c raised running capacity at every age tested.

   The science

   Reynolds 2021 showed MOTS-c improved physical capacity in young, middle-aged and old mice, and that exercise raises MOTS-c in human muscle almost 12-fold; exogenous MOTS-c plus exercise may amplify the signal, which is untested. A single dose raised running time 12% in untrained mice (Hyatt 2022), and a 2025 study found MOTS-c restored mitochondrial respiration in the hearts of rats with type 2 diabetes (Pham 2025).

   Sources

   - Reynolds et al. (2021)
   - Hyatt et al. (2022)
   - Pham et al. (2025)

   Updated Sep 2026
3. Day 28–56 Animal

   ### Weeks 4 to 8: check your markers

   If you track fasting glucose or wear a CGM, this is a sensible window to look for movement; the insulin-sensitivity gains so far come from mice. Commonly reported: steadier energy, and for some modest body-composition changes.

   The science

   A 2024 meta-analysis of 7 observational studies found blood MOTS-c lower in type 2 diabetes but higher in obesity (Zhou 2024), so it isn't a simple marker of metabolic health; whether people with low MOTS-c respond more to injections is untested. A 2025 Experimental & Molecular Medicine paper showed MOTS-c prevented islet senescence in aged mice (Kong 2025).

   Sources

   - Zhou et al. (2024)
   - Kong et al. (2025)

   Updated Sep 2026
4. Day 56–84 Animal

   ### Diminishing returns + cycle point

   Community protocols commonly run 6–12 weeks, but the window is convention rather than evidence — no human interventional data defines an endpoint. If metabolic markers moved, a break here lets you measure what holds; if nothing's shifted, running longer probably won't change that.

   The science

   A 2023 review notes that no effective way to use MOTS-c in the clinic has been developed (Zheng 2023). No interventional human trial has published as of September 2026: the rodent mechanism work is solid, but human dosing is extrapolated from it.

   Sources

   - Zheng et al. (2023)

   Updated Sep 2026
5. Any day Animal

   ### What MOTS-c is built on

   MOTS-c is genuinely novel: encoded in your mitochondrial DNA, not your nuclear DNA. The rodent work across metabolic disease, exercise capacity and aging is strong; in people there are only observational studies of natural blood levels, and no trial of the peptide itself.

   The science

   Discovered in 2015 by Dr. Changhan Lee at USC. A 2024 meta-analysis of 7 observational studies found lower MOTS-c levels in type 2 diabetes (Zhou 2024). Rodent work is rich (AMPK, PGC-1α, islet senescence protection; Kong 2025). Interventional human data is the missing piece, and FDA (April 2026) says it has found no human exposure data.

   Sources

   - Lee et al. (2015)
   - Zhou et al. (2024)
   - Kong et al. (2025)

   Updated Sep 2026
6. With Retatrutide, Tirzepatide and Semaglutide Community

   ### Why MOTS-c pairs with GLP-1s

   Two different axes of metabolic health: GLP-1 drugs work on appetite and insulin from the brain-gut side, while MOTS-c works at the mitochondrial level. Commonly reported: steadier energy through a GLP-1 deficit.

   The science

   No interaction or combination data exist for these pairs. Mechanistically: GLP-1 drives satiety and the pancreatic insulin response; MOTS-c drives AMPK, mitochondrial biogenesis and muscle glucose uptake in mice. The mechanisms barely overlap, which is the rationale for stacking; it hasn't been tested.

   Sources

   - Lee et al. (2015)
   - Reynolds et al. (2021)

   Updated Apr 2026

Day 1 is the day you start it.

Mouse and cell studies; human data are observational only, with no trials. Effects may be subtle.

Preliminary research

## A typical run.

### Run notes

- **Cycle:** 4–8 week cycles common, 2–3× per year. Common splits: Mon/Thu (2× weekly) or Mon/Wed/Fri (3× weekly). Limited long-term human data — none on continuous dosing. Community practice — opinions vary. Not a clinical recommendation.
- **Timing:** Morning injection, pre-exercise or with breakfast for metabolic effect.
- **Routes:** SubQ injection, IM injection
- **Stacks:** Humanin, SS-31, Ipamorelin

## Safety.

### Common side effects

- Injection site reaction
- Mild fatigue first week

#### Interactions

No published human interaction studies exist. Because MOTS-c affects glucose and insulin sensitivity, a mechanism-based consideration applies when combined with insulin or other antidiabetic agents, and glucose monitoring is worth discussing with a clinician. It is frequently stacked with GLP-1 agonists for metabolic goals — no combination-specific human data exists. No documented interaction with SSRIs, anticoagulants, or thyroid meds.

### Safety notes

MOTS-c is a mitochondrial-derived peptide regulating glucose and metabolic homeostasis; animal toxicology has been favorable at studied doses, but it has not been established as safe in humans: FDA (April 2026) says it has found no human exposure data for MOTS-c by any route and flags a possible risk of immune reactions to compounded versions. Community-reported effects include transient fatigue (often in the first 1-3 weeks), mild injection-site reactions, and occasional GI upset or palpitations. Because it influences glucose metabolism, glucose-relevant monitoring is a reasonable topic for your clinician. Long-term human safety is unknown.

## Goes with.

- [Humanin](https://pepvault.app/peptides/humanin)
- [SS-31](https://pepvault.app/peptides/ss-31)
- [Ipamorelin](https://pepvault.app/peptides/ipamorelin)

- ### In the Longevity Core stack

  Mitochondrial health & cellular-aging stack

  With [Epitalon](https://pepvault.app/peptides/epitalon) and [SS-31](https://pepvault.app/peptides/ss-31)
- ### In the Metabolic Reset stack

  Triple-agonist appetite control + mitochondrial metabolic optimization

  With [Retatrutide](https://pepvault.app/peptides/retatrutide)

## Compared with.

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)

## Questions people ask.

### What is MOTS-c?

A peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell. In mice it activates AMPK, the pathway exercise triggers, improving insulin sensitivity and exercise capacity, which is why it's called an "exercise mimetic".

### How is MOTS-c dosed in research?

The research range for MOTS-c is 5–10 mg, 2–3× weekly. Studied in research — not a recommendation.

### How long does MOTS-c last?

The half-life of MOTS-c is hours (short).

### What do people report on MOTS-c?

Commonly reported on MOTS-c: more energy and better workout endurance over the first weeks, sometimes after a week or two of feeling tired. No human trial has tested it yet.

### Is MOTS-c safe?

The research basis for MOTS-c is emerging: primarily preclinical / limited human data. Common side effects in the library: injection site reaction and mild fatigue first week.

### What does MOTS-c stack with?

Common stacks for MOTS-c: Humanin, SS-31 and Ipamorelin. Curated stacks with MOTS-c: Longevity Core and Metabolic Reset.

## Research.

The literature

### Search the latest research

[PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-c) [Google Scholar](https://scholar.google.com/scholar?q=MOTS-c)

Guide

### [What to take alongside each peptide](https://pepvault.app/guides/what-to-take-with-peptides)

Read the guide

## Reference.

- **Cadence:** 2–3× weekly
- **Half-life:** Hours Hours (short)
- **Research basis:** Emerging Primarily preclinical / limited human data

## More longevity peptides

- [NAD+ 50–100 mg](https://pepvault.app/peptides/nad)
- [Glutathione 100–600 mg](https://pepvault.app/peptides/glutathione)
- [Epitalon 5–10 mg](https://pepvault.app/peptides/epitalon)
- [FOXO4-DRI 1–2 mg](https://pepvault.app/peptides/foxo4-dri)
- [Pinealon 100–200 mcg](https://pepvault.app/peptides/pinealon)
- [Vesugen No reference dose](https://pepvault.app/peptides/vesugen)

## Free tools

- [MOTS-c dose guide](https://pepvault.app/lab/dosage/mots-c)
- [Injection guide (3D)](https://pepvault.app/lab/injection)
- [Peptide Sky (3D)](https://pepvault.app/lab/sky)
- [Peptide tier list](https://pepvault.app/lab/tiers)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)

PepVault for iPhone

## Track MOTS-c in PepVault

Log every dose, with reminders on your schedule. 7 days free on the yearly plan for new subscribers.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-cta&mt=8)

[Open the calculator](https://pepvault.app/tools/reconstitution-calculator) [How the vial count works](https://pepvault.app/peptide-vial-tracker-app) [Explore the live demo](https://pepvault.app/login)

Reviewed September 2026 [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault